Pravastatin Therapy Among All Ethnic Groups of CARE Reduced Primary End Point Events in Carriers of the KIF6 719Arg Allele, but not in Noncarriers
Artículo académico
Background: In a previous analysis of CARE that included only European American patients and analyzed only an MI end point, carriers of the 719Arg allele of KIF6, but not noncarriers, received event reduction from pravastatin. Therefore, we asked whether in all ethnic groups of CARE, pravastatin reduced primary end point events in carriers but not in noncarriers.
Methods: The effect of pravastatin on primary end point events (MI or fatal CHD) was investigated in Cox models separately for 719Arg (rs20455) carriers and noncarriers. To adjust for population structure, we included as covariates self-reported ethnicity or principal components of genetic heterogeneity calculated by EIGENSTRAT.
Results: After adjustment for age, sex, and ethnicity, we found that pravastatin reduced events in carriers (HR=0.63; 95%CI, 0.49-0.83, Figure) but not in noncarriers (HR=1.01; 95%CI, 0.69-1.45): P interaction =0.049. After adjustment for age, sex, traditional risk factors, and principal components, pravastatin reduced events in carriers of KIF6 719Arg (HR=0.64; 95%CI, 0.49-0.85) but not in noncarriers (HR=0.90; 95%CI, 0.62- 1.32): P interaction=0.14.
Conclusion: After adjusting for population structure in this study of CARE, pravastatin reduced primary end point events in carriers of the KIF6 719Arg allele, but not in noncarriers.
